• Aline Hajj, Lydia Khabbaz, Jean-Louis Laplanche, and Katell Peoc'h.
• Laboratoire de Pharmacologie Clinique et Pharmacocinétique, Faculté de Pharmacie, Université Saint Joseph, Beyrouth, Liban, Lebanon.
• Pharmacogenomics. 2013 Apr 1; 14 (5): 575-85.

AbstractOpioids are the cornerstone of analgesic therapy and are used as a substitution therapy for opiate addiction. Interindividual variability in response to opioids is a significant challenge in the management of pain and substitution. Therefore, treatment with opioids requires a careful individualization of dosage to achieve an appropriate balance of efficacy and adverse effects and, consequently, avoid toxicity, particularly respiratory depression, sedation and for some, cardiac ventricular fibrillations. Many studies have investigated the association between genetic factors and the variability of response to opioids. Variants in genes encoding proteins implied in opioid pharmacokinetics (absorption, distribution, metabolism, excretion and toxicity), together with those implied in opioids direct and indirect pharmacodynamics (genes of opioid receptors and monoaminergic systems), are the most studied. Many association studies have not been replicated. The purpose of this article is to summarize pharmacogenetic data associated with some opioids frequently encountered in managed care settings.

24 keywords...

hide…